NO323815B1 - Karbapenemantibiotikum,farmasoytisk preparat omfattende dette og fremgangsmate for stabilisering av karbapenemantibiotikum. - Google Patents

Karbapenemantibiotikum,farmasoytisk preparat omfattende dette og fremgangsmate for stabilisering av karbapenemantibiotikum. Download PDF

Info

Publication number: NO323815B1
Authority: NO; Norway
Prior art keywords: compound; pharmaceutically acceptable; formula; hydrate; acceptable salt
Prior art date: 1996-05-28

Application number

NO19980380A

Other languages

English (en)

Norwegian (no)

Other versions

NO980380L (no

NO980380D0 (no

Inventor

Jeffrey A Zimmerman

John M Williams

Paul A Bergquist

Lisa M Dimichele

David C Dubost

Michael J Kaufman

Daniel Richard Sidler

William A Hunke

Original Assignee

Merck & Co Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-05-28

Filing date

1998-01-28

Publication date

2007-07-09

1996-06-18 Priority claimed from GBGB9612668.5A external-priority patent/GB9612668D0/en

1998-01-28 Application filed by Merck & Co Inc filed Critical Merck & Co Inc

1998-01-28 Publication of NO980380D0 publication Critical patent/NO980380D0/no

1998-03-16 Publication of NO980380L publication Critical patent/NO980380L/no

2007-07-09 Publication of NO323815B1 publication Critical patent/NO323815B1/no

Links

YZBQHRLRFGPBSL-RXMQYKEDSA-N carbapenem Chemical compound C1C=CN2C(=O)C[C@H]21 YZBQHRLRFGPBSL-RXMQYKEDSA-N 0.000 title claims description 12
238000000034 method Methods 0.000 title claims description 10
230000000087 stabilizing effect Effects 0.000 title claims description 3
239000008194 pharmaceutical composition Substances 0.000 title abstract description 3
230000003115 biocidal effect Effects 0.000 title description 4
150000001875 compounds Chemical class 0.000 claims abstract description 71
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims abstract description 50
150000003839 salts Chemical class 0.000 claims abstract description 34
239000001569 carbon dioxide Substances 0.000 claims abstract description 25
229910002092 carbon dioxide Inorganic materials 0.000 claims abstract description 25
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 40
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 30
239000000825 pharmaceutical preparation Substances 0.000 claims description 24
229910000029 sodium carbonate Inorganic materials 0.000 claims description 20
229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 15
235000017557 sodium bicarbonate Nutrition 0.000 claims description 15
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 10
239000003112 inhibitor Substances 0.000 claims description 8
239000003937 drug carrier Substances 0.000 claims description 6
125000002091 cationic group Chemical group 0.000 claims description 2
DHSUYTOATWAVLW-WFVMDLQDSA-N cilastatin Chemical group CC1(C)C[C@@H]1C(=O)N\C(=C/CCCCSC[C@H](N)C(O)=O)C(O)=O DHSUYTOATWAVLW-WFVMDLQDSA-N 0.000 claims description 2
229960004912 cilastatin Drugs 0.000 claims description 2
229940122344 Peptidase inhibitor Drugs 0.000 claims 1
239000000651 prodrug Substances 0.000 abstract 1
229940002612 prodrug Drugs 0.000 abstract 1
238000002360 preparation method Methods 0.000 description 24
239000000203 mixture Substances 0.000 description 20
238000009472 formulation Methods 0.000 description 10
239000000243 solution Substances 0.000 description 10
239000003814 drug Substances 0.000 description 8
239000000843 powder Substances 0.000 description 8
238000004090 dissolution Methods 0.000 description 7
229940079593 drug Drugs 0.000 description 7
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
239000000872 buffer Substances 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical class [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 5
239000011575 calcium Substances 0.000 description 5
239000003795 chemical substances by application Substances 0.000 description 5
239000003085 diluting agent Substances 0.000 description 5
-1 sodium carbonate or Chemical compound 0.000 description 5
UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 4
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
239000003755 preservative agent Substances 0.000 description 4
239000011734 sodium Substances 0.000 description 4
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
230000000844 anti-bacterial effect Effects 0.000 description 3
229940041011 carbapenems Drugs 0.000 description 3
150000001768 cations Chemical class 0.000 description 3
208000015181 infectious disease Diseases 0.000 description 3
239000004615 ingredient Substances 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
150000002500 ions Chemical class 0.000 description 3
239000007788 liquid Substances 0.000 description 3
229910052708 sodium Inorganic materials 0.000 description 3
HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
208000035143 Bacterial infection Diseases 0.000 description 2
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical class NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
229930195725 Mannitol Natural products 0.000 description 2
MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
239000002253 acid Substances 0.000 description 2
208000022362 bacterial infectious disease Diseases 0.000 description 2
BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 2
230000037396 body weight Effects 0.000 description 2
229940098773 bovine serum albumin Drugs 0.000 description 2
239000008121 dextrose Substances 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
239000008103 glucose Substances 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
239000008101 lactose Substances 0.000 description 2
239000003589 local anesthetic agent Substances 0.000 description 2
229960005015 local anesthetics Drugs 0.000 description 2
239000000594 mannitol Substances 0.000 description 2
235000010355 mannitol Nutrition 0.000 description 2
229920006316 polyvinylpyrrolidine Polymers 0.000 description 2
239000011591 potassium Substances 0.000 description 2
229910052700 potassium Inorganic materials 0.000 description 2
239000007787 solid Substances 0.000 description 2
239000008227 sterile water for injection Substances 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
CGEJGVJCYONJRA-UHFFFAOYSA-N 3-Hydroxyheptan-2-one Chemical compound CCCCC(O)C(C)=O CGEJGVJCYONJRA-UHFFFAOYSA-N 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
108020004256 Beta-lactamase Proteins 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical class OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical class OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
239000004386 Erythritol Substances 0.000 description 1
UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
241000276498 Pollachius virens Species 0.000 description 1
PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Chemical class OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
DZJXKISLUDYJSV-UHFFFAOYSA-N [N].C1CCNC1 Chemical group [N].C1CCNC1 DZJXKISLUDYJSV-UHFFFAOYSA-N 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
239000011149 active material Substances 0.000 description 1
241001148470 aerobic bacillus Species 0.000 description 1
HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Chemical class OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000003125 aqueous solvent Substances 0.000 description 1
229960000686 benzalkonium chloride Drugs 0.000 description 1
229960005274 benzocaine Drugs 0.000 description 1
CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
102000006635 beta-lactamase Human genes 0.000 description 1
GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000002775 capsule Substances 0.000 description 1
150000004657 carbamic acid derivatives Chemical class 0.000 description 1
150000004649 carbonic acid derivatives Chemical class 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
239000001913 cellulose Chemical class 0.000 description 1
229920002678 cellulose Chemical class 0.000 description 1
239000007979 citrate buffer Substances 0.000 description 1
239000006071 cream Substances 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
WDRWZVWLVBXVOI-QTNFYWBSSA-L dipotassium;(2s)-2-aminopentanedioate Chemical compound [K+].[K+].[O-]C(=O)[C@@H](N)CCC([O-])=O WDRWZVWLVBXVOI-QTNFYWBSSA-L 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
238000009826 distribution Methods 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
235000019414 erythritol Nutrition 0.000 description 1
229940009714 erythritol Drugs 0.000 description 1
230000029142 excretion Effects 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
239000007789 gas Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
238000005469 granulation Methods 0.000 description 1
230000003179 granulation Effects 0.000 description 1
239000008311 hydrophilic ointment Substances 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
229960000367 inositol Drugs 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
229960004194 lidocaine Drugs 0.000 description 1
230000033001 locomotion Effects 0.000 description 1
239000006210 lotion Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
229960003194 meglumine Drugs 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
235000013919 monopotassium glutamate Nutrition 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
229940053973 novocaine Drugs 0.000 description 1
239000003973 paint Substances 0.000 description 1
235000019629 palatability Nutrition 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
229940120090 pontocaine Drugs 0.000 description 1
MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
239000002994 raw material Substances 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
235000004400 serine Nutrition 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
239000002904 solvent Substances 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
239000003826 tablet Substances 0.000 description 1
GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
241001148471 unidentified anaerobic bacterium Species 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D499/88—Compounds with a double bond between positions 2 and 3 and a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
- C07D499/887—Compounds with a double bond between positions 2 and 3 and a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with a hetero atom or a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 3
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D477/00—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring
- C07D477/10—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
- C07D477/12—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6
- C07D477/16—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6 with hetero atoms or carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 3
- C07D477/20—Sulfur atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

NO19980380A 1996-05-28 1998-01-28 Karbapenemantibiotikum,farmasoytisk preparat omfattende dette og fremgangsmate for stabilisering av karbapenemantibiotikum. NO323815B1 (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US1851896P	1996-05-28	1996-05-28
GBGB9612668.5A GB9612668D0 (en)	1996-06-18	1996-06-18	Carbapenem antibiotic composition and method of preparation
PCT/US1997/008831 WO1997045430A1 (en)	1996-05-28	1997-05-23	Carbapenem antibiotic, composition and method of preparation

Publications (3)

Publication Number	Publication Date
NO980380D0 NO980380D0 (no)	1998-01-28
NO980380L NO980380L (no)	1998-03-16
NO323815B1 true NO323815B1 (no)	2007-07-09

Family

ID=26309530

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19980380A NO323815B1 (no)	1996-05-28	1998-01-28	Karbapenemantibiotikum,farmasoytisk preparat omfattende dette og fremgangsmate for stabilisering av karbapenemantibiotikum.

Country Status (33)

Country	Link
EP (1)	EP0863901B1 (de)
JP (2)	JPH11509871A (de)
KR (2)	KR100403497B1 (de)
CN (1)	CN1067074C (de)
AT (1)	ATE252584T1 (de)
AU (1)	AU710102B2 (de)
BG (1)	BG63821B1 (de)
CA (1)	CA2227994C (de)
CO (1)	CO4940412A1 (de)
CY (1)	CY2437B1 (de)
CZ (1)	CZ296381B6 (de)
DE (1)	DE69725696T2 (de)
DK (1)	DK0863901T3 (de)
DZ (1)	DZ2242A1 (de)
EA (1)	EA000534B1 (de)
EE (1)	EE04678B1 (de)
ES (1)	ES2208907T3 (de)
HR (1)	HRP970281B1 (de)
HU (1)	HU229426B1 (de)
ID (1)	ID16974A (de)
IL (1)	IL123078A (de)
IS (1)	IS2353B (de)
MX (1)	MX9800808A (de)
NO (1)	NO323815B1 (de)
NZ (1)	NZ329649A (de)
PL (1)	PL188917B1 (de)
PT (1)	PT863901E (de)
RS (1)	RS49583B (de)
SI (1)	SI0863901T1 (de)
SK (1)	SK284359B6 (de)
TR (1)	TR199800146T1 (de)
TW (1)	TW434014B (de)
WO (1)	WO1997045430A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU725298B2 (en) *	1996-10-28	2000-10-12	Merck & Co., Inc.	Stabilized carbapenem antibiotic compositions and method of making
US6180783B1 (en) *	1997-06-16	2001-01-30	Merck & Co., Inc.	Stabilized carbapenem intermediates and improved process for carbapenem synthesis
WO1998057973A1 (en) *	1997-06-16	1998-12-23	Merck & Co., Inc.	Stabilized carbapenem intermediates and synthetic use
US6504027B1 (en)	1998-03-02	2003-01-07	Merck & Co., Inc.	Decarboxylation process for synthesizing carbapenem antibiotics
ES2234689T3 (es) *	1999-10-29	2005-07-01	MERCK & CO., INC.	Procedimiento de preparacion de composiciones de antibioticos a base de carbapenemo.
AR035728A1 (es)	2001-01-16	2004-07-07	Merck & Co Inc	Proceso perfeccionado para la sintesis de carbapenem
CN101357918B (zh) *	2007-06-22	2011-05-18	山东轩竹医药科技有限公司	含有异硫脲基巯基吡咯烷的培南衍生物
CN101367815B (zh) *	2007-06-28	2012-07-04	山东轩竹医药科技有限公司	六元环甲酰胺取代的巯基吡咯烷碳青霉烯化合物
US20100256107A1 (en) *	2007-12-12	2010-10-07	Dainippon Sumitomo Pharma Co., Ltd.	Preparation composition
CN101550138B (zh) *	2008-04-03	2011-05-18	山东轩竹医药科技有限公司	巯基氮杂环烷酰胺醇取代的培南衍生物
EP2505191A1 (de) *	2008-06-11	2012-10-03	Ranbaxy Laboratories Limited	Lypholisierte Carbapenem-Antibiotikumzusammensetzung
WO2010113492A1 (ja)	2009-03-31	2010-10-07	三菱マテリアル株式会社	含フッ素ｎ－アルキルスルホニルイミド化合物及びその製造方法、並びにイオン性化合物の製造方法
GB2483591A (en)	2009-06-25	2012-03-14	Shell Int Research	Water injection systems and methods
US8889384B2 (en)	2010-10-07	2014-11-18	Shell Oil Company	Process for the production of alcohols from biomass
BR112013010725B1 (pt)	2010-11-05	2018-12-04	Shell Internationale Research Maatschappij B.V.	método para tratamento de biomassa para a produção de açúcares a partir de materiais contendo polissacarídeos, para uso em biocombustíveis ou outros produtos de elevado valor, e, composição
US8609379B2 (en)	2010-12-20	2013-12-17	Shell Oil Company	Process for the production of alcohols from biomass
EP2791344B1 (de)	2011-12-15	2016-02-24	Shell Internationale Research Maatschappij B.V.	Verfahren zur behandlung von nebenprodukten aus der ethanolherstellung
CN104364366B (zh)	2012-05-17	2017-09-08	国际壳牌研究有限公司	处理生物质材料的方法和系统
CN103860485A (zh) *	2012-12-18	2014-06-18	深圳市海滨制药有限公司	一种厄他培南钠冻干制剂及其制备方法
US20150299739A1 (en)	2014-04-17	2015-10-22	Shell Oil Company	Processes for producing fermentation products
WO2016025678A1 (en)	2014-08-14	2016-02-18	Shell Oil Company	Process for preparing furfural from biomass

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES8502863A1 (es) *	1982-09-10	1985-02-01	Glaxo Group Ltd	Un procedimiento para la produccion de un recipiente hermeticamente cerrado que contiene al menos un antibiotico de beta-lactama.
GB9202298D0 (en) *	1992-02-04	1992-03-18	Ici Plc	Antibiotic compounds
CA2091309A1 (en) *	1992-03-26	1993-09-27	Frederic H. Jung	Antibiotic compounds

1997
- 1997-05-21 HR HR970281A patent/HRP970281B1/xx not_active IP Right Cessation
- 1997-05-23 DE DE69725696T patent/DE69725696T2/de not_active Expired - Lifetime
- 1997-05-23 NZ NZ329649A patent/NZ329649A/en not_active IP Right Cessation
- 1997-05-23 MX MX9800808A patent/MX9800808A/es active IP Right Grant
- 1997-05-23 WO PCT/US1997/008831 patent/WO1997045430A1/en not_active Ceased
- 1997-05-23 EE EE9800022A patent/EE04678B1/xx unknown
- 1997-05-23 ES ES97925725T patent/ES2208907T3/es not_active Expired - Lifetime
- 1997-05-23 JP JP9542800A patent/JPH11509871A/ja not_active Withdrawn
- 1997-05-23 AU AU30775/97A patent/AU710102B2/en not_active Expired
- 1997-05-23 EP EP97925725A patent/EP0863901B1/de not_active Expired - Lifetime
- 1997-05-23 SI SI9730603T patent/SI0863901T1/xx unknown
- 1997-05-23 AT AT97925725T patent/ATE252584T1/de active
- 1997-05-23 TR TR1998/00146T patent/TR199800146T1/xx unknown
- 1997-05-23 KR KR10-2001-7008925A patent/KR100403497B1/ko not_active Expired - Lifetime
- 1997-05-23 IL IL12307897A patent/IL123078A/en not_active IP Right Cessation
- 1997-05-23 SK SK109-98A patent/SK284359B6/sk not_active IP Right Cessation
- 1997-05-23 EA EA199800180A patent/EA000534B1/ru not_active IP Right Cessation
- 1997-05-23 CA CA002227994A patent/CA2227994C/en not_active Expired - Lifetime
- 1997-05-23 KR KR1019980700717A patent/KR100344479B1/ko not_active Expired - Lifetime
- 1997-05-23 CZ CZ0025398A patent/CZ296381B6/cs not_active IP Right Cessation
- 1997-05-23 PL PL97324746A patent/PL188917B1/pl unknown
- 1997-05-23 RS YUP-41/98A patent/RS49583B/sr unknown
- 1997-05-23 DK DK97925725T patent/DK0863901T3/da active
- 1997-05-23 PT PT97925725T patent/PT863901E/pt unknown
- 1997-05-23 HU HU9901567A patent/HU229426B1/hu unknown
- 1997-05-23 CN CN97190911A patent/CN1067074C/zh not_active Expired - Lifetime
- 1997-05-26 CO CO97028781A patent/CO4940412A1/es unknown
- 1997-05-26 ID IDP971736A patent/ID16974A/id unknown
- 1997-05-27 DZ DZ970091A patent/DZ2242A1/fr active
- 1997-05-28 TW TW086107254A patent/TW434014B/zh not_active IP Right Cessation
1998
- 1998-01-27 IS IS4663A patent/IS2353B/is unknown
- 1998-01-28 NO NO19980380A patent/NO323815B1/no not_active IP Right Cessation
- 1998-02-24 BG BG102273A patent/BG63821B1/bg unknown
2004
- 2004-04-26 CY CY0400030A patent/CY2437B1/xx unknown
2008
- 2008-10-17 JP JP2008268213A patent/JP5255983B2/ja not_active Expired - Lifetime

Also Published As

Publication number	Publication date
RS49583B (sr)	2007-04-10
ID16974A (id)	1997-11-27
HUP9901567A2 (hu)	1999-09-28
AU710102B2 (en)	1999-09-16
CY2437B1 (en)	2004-11-12
EP0863901A1 (de)	1998-09-16
CA2227994A1 (en)	1997-12-04
CN1198162A (zh)	1998-11-04
WO1997045430A1 (en)	1997-12-04
NZ329649A (en)	1998-11-25
TW434014B (en)	2001-05-16
SI0863901T1 (en)	2004-04-30
JP5255983B2 (ja)	2013-08-07
ES2208907T3 (es)	2004-06-16
KR100403497B1 (ko)	2003-10-30
EE9800022A (et)	1998-08-17
EA199800180A1 (ru)	1998-08-27
PL188917B1 (pl)	2005-05-31
HK1016176A1 (en)	1999-10-29
CZ25398A3 (cs)	1998-07-15
HU229426B1 (en)	2013-12-30
JPH11509871A (ja)	1999-08-31
EA000534B1 (ru)	1999-10-28
IS4663A (is)	1998-01-27
IL123078A0 (en)	1998-09-24
ATE252584T1 (de)	2003-11-15
DZ2242A1 (fr)	2002-12-18
IS2353B (is)	2008-04-15
IL123078A (en)	2002-03-10
DE69725696D1 (de)	2003-11-27
MX9800808A (es)	1998-04-30
CA2227994C (en)	2002-06-25
CN1067074C (zh)	2001-06-13
AU3077597A (en)	1998-01-05
SK10998A3 (en)	1998-08-05
BG102273A (bg)	1998-09-30
PL324746A1 (en)	1998-06-08
TR199800146T1 (xx)	1998-06-22
HRP970281B1 (en)	2002-04-30
KR19990036052A (de)	1999-05-25
KR100344479B1 (ko)	2002-10-31
NO980380L (no)	1998-03-16
CZ296381B6 (cs)	2006-03-15
HRP970281A2 (en)	1998-06-30
NO980380D0 (no)	1998-01-28
HUP9901567A3 (en)	2000-03-28
BG63821B1 (bg)	2003-02-28
CO4940412A1 (es)	2000-07-24
DE69725696T2 (de)	2004-07-29
SK284359B6 (sk)	2005-02-04
EP0863901B1 (de)	2003-10-22
YU4198A (sh)	1998-12-23
DK0863901T3 (da)	2004-02-16
EE04678B1 (et)	2006-08-15
PT863901E (pt)	2004-02-27
JP2009084284A (ja)	2009-04-23

Publication	Publication Date	Title
NO323815B1 (no)	2007-07-09	Karbapenemantibiotikum,farmasoytisk preparat omfattende dette og fremgangsmate for stabilisering av karbapenemantibiotikum.
EP1207881B1 (de)	2015-04-01	Benzamidderivate enthaltende pharmazeutische Mittel
DE60131441T2 (de)	2008-09-18	Verfahren zur formulierung antibiotischer verbindungen
US5952323A (en)	1999-09-14	Carbapenem antibiotic
CA1043261A (en)	1978-11-28	Cephalosporin-type antibiotic composition
KR930001830B1 (ko)	1993-03-15	항균성 동결건조 제제
US6060498A (en)	2000-05-09	Composition containing antitumor agent
EP1326608B1 (de)	2005-12-07	Stabilisierte arzneizusammensetzungen von oxapenem-3-carbonsäuren durch gefriertrocknen mit pharmazeutischen trägermitteln
JP2000508343A (ja)	2000-07-04	安定化されたカルバペネム抗生物質組成物及びその製造方法
BR9702231B1 (pt)	2019-03-12	composição farmacêutica, composto, e, processo para estabilizar um carbapenem
CA2247329C (en)	2006-07-04	Composition containing antitumor agent

Legal Events

Date	Code	Title	Description
2017-06-06	MK1K	Patent expired